BIOCIUS’s Dr. Maxine Jonas will also give a talk entitled, “The RF-300, an integrated automated SPE-MS System for high-throughput ADME sample analysis” on Wednesday, January 27 at 9:00 am, (Look for Track: High throughput Technologies, Session: Parallel Process Advances). To arrange a private in-person meeting while at the conference, please send a message to firstname.lastname@example.org.
RapidFire mass spectrometry greatly decreases the bottlenecks that occur during drug discovery. By enabling automated sample preparation at a rate of up to six seconds per sample and integrating seamlessly to the mass spectrometer, RapidFire enhances high-throughput screening of candidate drug compounds and in vitro ADME assays.
RapidFire allows for the analysis of a wide range of otherwise intractable targets such as triglycerides, lipids, fatty acids, prostaglandins, steroids, coenzyme A derivatives, neurotransmitters, epigenetic targets, anti-fungals and anti-infectives, which are difficult to study using traditional methods such as fluorescence or radiolabels. The RapidFire system can be used for a variety of in vitro ADME applications, including: CYP inhibition, metabolic stability, P-glycoprotein inhibition, plasma protein binding, permeability assays - Caco, PAMPA and CYP induction. RapidFire hardware is available as a solution in our collaborators' laboratories or as a contract research service in the BIOCIUS laboratory.
Spun out from BioTrove in December 2009, the RapidFire business unit formed BIOCIUS Life Sciences to provide the biopharmaceutical industry with faster answers: products and services committed to speed and accuracy in drug discovery. Used by 13 of the top 15 pharmaceutical companies, BIOCIUS’s products and contract research services enable our partners to exceed their business goals. For more information, select from the Related Resources below or visit the company website.